The evolution of modern notions about bladder cancer

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review details the evolution in the researchers’ perspective of bladder cancer over the past five decades. The history of the study, pathogenesis, etiology, and the clinical significance of urinary bladder are briefly discussed. The review presents currently prominent theories regarding the pathogenesis of urinary bladder neoplasms and the foundational research in this field. The article briefly discusses the molecular changes the development of bladder cancer and studies of the urine microbiome during oncogenesis

Full Text

Restricted Access

About the authors

Artem A. Yurchenko

Krasnoyarsk Clinical Regional Hospital

Author for correspondence.
Email: likebrando@yandex.ru
ORCID iD: 0000-0003-0979-6909
Russian Federation, Krasnoyarsk

Mikhail A. Firsov

Krasnoyarsk Clinical Regional Hospital; Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: firsma@mail.ru
ORCID iD: 0000-0002-0887-0081
SPIN-code: 6308-6260

MD, Cand. Sci. (Med.)

Russian Federation, Krasnoyarsk; Krasnoyarsk

Ruslan A. Zukov

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I.Kryzhanovsky RSBHE

Email: zukov_rus@mail.ru
ORCID iD: 0000-0002-7210-3020
SPIN-code: 3632-8415

Dr. Sci. (Med.), Professor

Russian Federation, Krasnoyarsk; Krasnoyarsk

Evgeny V. Slepov

Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I.Kryzhanovsky RSBHE

Email: slepov99@mail.ru
ORCID iD: 0000-0002-3787-3126
SPIN-code: 2097-0304

MD, Cand. Sci. (Biol.)

Russian Federation, Krasnoyarsk

References

  1. Assotsiatsiya onkologov Rossii. Klinicheskie rekomendatsii. Rak mochevogo puzyrya. 2020. (In Russ).
  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi: 10.1016/j.ejca.2012.12.027
  3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–3044. doi: 10.1002/ijc.21731
  4. Shiff C, Veltri R, Naples J, et al. Ultrasound verification of bladder damage is associated with known biomarkers of bladder cancer in adults chronically infected with Schistosoma haematobium in Ghana. Trans R Soc Trop Med Hyg. 2006;100(9):847–854. doi: 10.1016/j.trstmh.2005.10.010
  5. Leonov MG, Shelyakina TV, Tkhagapso AA. Otsenka faktorov riska vozniknoveniya raka mochevogo puzyrya. Glavnyi vrach Yuga Rossii. 2015;(2):34. (In Russ).
  6. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89(3):630–639. doi: 10.1002/1097-0142(20000801)89:3<630::aid-cncr19>3.3.co;2-h
  7. Wallace DM. Occupational urothelial cancer. Br J Urol. 1988;61(3):175–182. doi: 10.1111/j.1464-410x.1988.tb06374.x
  8. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17(9):2876–2881. doi: 10.1200/JCO.1999.17.9.2876
  9. Shinka T, Sawada Y, Morimoto S, et al. Clinical study on urothelial tumors of dye workers in Wakayama City. J Urol. 1991;146(6):1504–1507. doi: 10.1016/s0022-5347(17)38151-x
  10. Harris AL, Neal DE. Bladder cancer – field versus clonal origin. N Engl J Med. 1992;326(11):759–761. doi: 10.1056/NEJM199203123261108
  11. Davidson DD, Cheng L. “Field cancerization” in the urothelium of the bladder. Anal Quant Cytol Histol. 2006;28(6):337–338.
  12. Wolf H, Hojgaard K. Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurrences. Lancet. 1983;2(8342):134–136. doi: 10.1016/s0140-6736(83)90117-4
  13. Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin of bladder cancer. N Engl J Med. 1992;326(11):737–740. doi: 10.1056/NEJM199203123261104
  14. Lunec J, Challen C, Wright C, et al. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet. 1992;339(8790):439–440. doi: 10.1016/0140-6736(92)90135-p
  15. Babaian AIu, Andreeva YuYu, Zaletaev DV, Nemtsova MV. Clonal origin of multiple foci of urinary bladder cancer. Arkhiv Patologii. 2012;74(5):44–50. (In Russ).
  16. Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005;11(18):6512–6519. doi: 10.1158/1078-0432.CCR-05-0891
  17. Chen PC, Yu HJ, Chang YH, Pan CC. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol. 2013;66(2):113–119. doi: 10.1136/jclinpath-2012-200944
  18. Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer. 2002;101(1):1–6. doi: 10.1002/ijc.10544
  19. Wu BK, Brenner C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep. 2014;9(5):1827–1840. doi: 10.1016/j.celrep.2014.10.063
  20. Heyn H, Sayols S, Moutinho C, et al. Linkage of DNA methylation quantitative trait loci to human cancer risk. Cell Rep. 2014;7(2):331–338. doi: 10.1016/j.celrep.2014.03.016
  21. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003;63(23):8108-8112.
  22. Tabin CJ, Bradley SM, Bargmann CI, et al. Mechanism of activation of a human oncogene. Nature. 1982;300(5888):143–149. doi: 10.1038/300143a0
  23. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001;20(16):1973–1980. doi: 10.1038/sj.onc.1204315
  24. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–322. doi: 10.1038/nature12965
  25. Cheng J, Huang H, Pak J, et al. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer research. 2003;63(1):179–185.
  26. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002;62(3):809–818.
  27. Kim J, Akbani R, Creighton CJ, et al. Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res. 2015;21(20):4514–4524. doi: 10.1158/1078-0432.CCR-14-1215
  28. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17–37. doi: 10.1016/j.cell.2013.03.002
  29. Zaghloul MS. Bladder cancer and schistosomiasis. J Egypt Natl Canc Inst. 2012;24(4):151–159. doi: 10.1016/j.jnci.2012.08.002
  30. Lopez-Beltran A, Escudero AL, Vicioso L, et al. Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br J Cancer. 1996;73(1):124–127. doi: 10.1038/bjc.1996.23
  31. De Gaetani C, Ferrari G, Righi E, et al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridisation. J Clin Pathol. 1999;52(2):103–106. doi: 10.1136/jcp.52.2.103
  32. Aso Y, Akaza H, Kotake T, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol. 1995;27(2):104–109. doi: 10.1159/000475138
  33. Yan Y, Chen YN, Zhao Q, et al. Helicobacter pylori infection with intestinal metaplasia: An independent risk factor for colorectal adenomas. World J Gastroenterol. 2017;23(8):1443–1449. doi: 10.3748/wjg.v23.i8.1443
  34. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–215. doi: 10.1016/j.chom.2013.07.007
  35. O’Donnell MA. Does the probiotic L. casei help prevent recurrence after transurethral resection for superficial bladder cancer? Nat Clin Pract Urol. 2008;5(10):526–527. doi: 10.1038/ncpuro1199
  36. Wu P, Zhang G, Zhao J, et al. Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. Front Cell Infect Microbiol. 2018;8:167. doi: 10.3389/fcimb.2018.00167.
  37. Bucevic Popovic V, Situm M, Chow CT, et al. The urinary microbiome associated with bladder cancer. Sci Rep. 2018;8(1):12157. doi: 10.1038/s41598-018-29054-w
  38. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664–3671. doi: 10.1200/JCO.2005.05.1771

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Yurchenko A.A., Firsov M.A., Zukov R.A., Slepov E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 014159 от 23.10.1995 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80673 от 23.03.2021 г
.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies